

FORM PTO-1449

Sheet 1 of 3

LIST OF DOCUMENTS CITED BY APPLICANTS

(Use several sheets if necessary)

ATTY. DOCKET NO. 7070

SERIAL NO. 09/09/646,984

APPLICANT Rubingh et al.

FILING DATE 9/25/2000

GROUP 1635 1652

U. S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
WJW	01	4,179,337	12/18/79	Davis et al.	435	181	
	02	4,248,786	02/03/81	Batz et al.	260	326	
	03	4,266,031	05/05/81	Tang et al.	435	188	
	04	4,556,554	12/03/85	Calvo	424	70	
	05	4,732,863	03/22/88	Tomasi et al.	436	547	
	06	4,760,025	07/26/88	Estell et al.	435	222	
	07	4,980,288	12/25/90	Bryan et al.	435	222	
	08	5,122,614	06/16/92	Zalipsky	548	520	
	09	5,133,968	07/28/92	Nakayama et al.	424	401	
	10	5,208,158	05/04/93	Bech et al.	435	219	
	11	5,230,891	07/27/93	Nakayama et al.	424	401	
	12	5,324,844	06/28/94	Zalipsky	548	520	
	13	5,414,135	05/09/95	Snow et al.	568/29	568/30	
	14	5,446,090	08/29/95	Harris	525	54	
	15	5,631,322	05/20/97	Veronese et al.	525	54.1	
	16	5,658,871	08/19/97	Batenburg et al.	252	174.12	
WJW	17	5,856,451	01/05/99	Olsen et al.	530	402	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
WJW	18	EP 0 215,662	03/25/87	EPO	A 61 K	37/54	
	19	EP 0 398 539	11/22/90	EPO	C12N	9/54	
	20	EP 0 405 901	01/02/91	EPO	C11D	3/386	
	21	EP 0 516,200	12/02/92	EPO	C11D	3/386	
	22	EP 0 584,876	03/02/94	EPO	A 61 K	47/48	
	23	EP 0 816,381	01/07/98	EPO	C07K	17/08	
	24	WO 87/05050	08/27/87	PCT	C12Q	1/68	
	25	WO 88/08028	10/20/88	PCT	C12N	15/00	
	26	WO 92/10755	06/25/92	PCT	G01N	33/53	
	27	WO 93/15189	08/05/93	PCT	C12N	9/96	
	28	WO 93/19731	10/14/93	PCT	A61K	7/48	
	29	WO 93/19732	10/14/93	PCT	A61K	7/48	
	30	WO 94/04193	03/03/94	PCT	A61K	47/48	
	31	WO 94/06905	03/31/94	PCT	C12N	9/54	X
	32	WO 95/07991	03/23/95	PCT	C12N	15/57	
	33	WO 95/10615	04/20/95	PCT	C12N	15/57	
	34	WO 95/29979	11/09/95	PCT	C11D	3/386	
	35	WO 95/30010	11/09/95	PCT	C12N	15/57	
	36	WO 96/09396	03/28/96	PCT	C12N	15/57	
	37	WO 96/16177	05/30/96	PCT	C12N	15/62	
	38	WO 96/17929	06/13/96	PCT	C12N	9/96	
	39	WO 96/40791	12/19/96	PCT	C07K	17/08	
	40	WO 96/40792	12/19/96	PCT	C07K	17/08	
	41	WO 97/07770	03/06/97	PCT	A61K	7/48	X
	42	WO 97/24421	07/10/97	PCT	C11D		
	43	WO 97/24427	07/10/97	PCT	C11D	3/386	
	44	WO 97/30148	08/21/97	PCT	C12N	9/96	
WJW	45	WO 97/37007	10/09/97	PCT	C12N	9/96	


EXAMINER

William W. Moore

DATE CONSIDERED

15 October 2000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
Sheet 2 of 3

LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 7070	SERIAL NO. 09/09/646,984
	APPLICANT Rubingh et al.	
	FILING DATE 9/25/2000	GROUP 1633 / 682


FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
<i>Algen</i>	46	WO 98/30682	07/16/98	PCT	C12N	9/96	
<i>Algen</i>	47	WO 98/35026	08/13/98	PCT	C12N	9/96	
<i>Algen</i>	48	WO 99/00489	01/07/99	PCT	C12N	9/96	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>Algen</i> ↑	49	Arlan, L.G. et al., "Antigenic and Allergenic Characteristics of the Enzymes Alcalase and Savinase by Crossed Immunoelectrophoresis and Crossed Radioimmuno-electrophoresis", INT. ARCH. ALLERGY. APPL. IMMUNOL., Vol. 91, pp. 278-284 (1990).
	50	Abuchowski, A. et al., "Cancer Therapy with Chemically Modified Enzymes. I. Antitumor Properties of Polyethylene Glycol-Asparaginase Conjugates", CANCER BIOCHEM. BIOPHYS., Vol. 7, pp. 175-186 (1984)
	51	Abuchowski, A. et al., "Soluble Polymer-Enzyme Adducts", Rutgers University, New Brunswick, NJ, Chapter 13, pp. 367-383.
	52	Bungy Poor Fard, G.A. et al., "T Cell Epitopes of the Major Fraction of Rye Grass Lolium Perenne (lol p I) Defined Using Overlapping Peptides in Vitro and In Vivo. I. Isoallergen Clone 1A", CLIN. EXP. IMMUNOL., Vol. 94, pp. 111-116 (1993).
	53	Caliceti, P. et al., "Active Site Protection of Proteolytic Enzymes by Poly(ethylene glycol) Surface Modification" JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS, Vol. 8, pp. 41-50 (Jan. 1993).
	54	Cunningham, B. C. et al., "Improvement in the alkaline stability of subtilisin using an efficient Random Mutagenesis and Screening Procedure", PROTEIN ENGINEERING, Vol. 1, No. 4, pp. 319-325 (Aug/Sept 1987).
	55	Davis, F. F. et al., "Reduction of Immunogenicity and Extension of Circulating Half-Life of Peptides and Proteins", PEPTIDE AND PROTEIN DRUG DELIVERY, Chpt. 21, pp.831-857, Lee, V. (ED), University of California School of Pharmacy, Los Angeles, CA.
	56	Delgado, C. et al., "The Uses and Properties of PEG-Linked Proteins", CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, Vol. 9, No. 3/4, pp. 249-304 (1992)
	57	Favre, C. et al., "Epitope Mapping of Recombinant Human Gamma Interferon Using Monoclonal Antibodies", MOLECULAR IMMUNOLOGY, VOL. 26, NO. 1, pp. 17-25 (1989).
	58	Francis, G.E. et al., "PEG-Modified Proteins", STABILITY OF PROTEIN PHARMACEUTICALS, PART B: IN VIVO PATHWAYS OF DEGRADATION AND STRATEGIES FOR PROTEIN STABILIZATION, edited by Ahern, T.J. and Mannin, M.C., Plenum Press, pp.235-263 (1992).
	59	Hopp, T.P. et al., "Prediction of Protein Antigenic Determinants from Amino Acid Sequences", PROC. NATL. ACAD. Sci., Vol. 78, NO. 6, pp. 3824-3828 (1981).
	60	Katre, N.V., "The Conjugation of Proteins with Polyethylene Glycol and Other Polymers", ADVANCED DRUG DELIVERY REVIEWS, Vol. 10, pp. 91-114 (1993).
	61	Khan, S.A. et al., "Polyethylene Glycol-modified Subtilisin Forms Microparticulate Suspensions in Organic Solvents", ENZYME MICROB. TECHNOLOGY, Vol. 14, pp. 96-100 (Feb. 1992).
	62	Masunaga, T. et al., "The Protease as a Cleansing Agent and Its Stabilization by Chemical Modification", IFSCC, pp. 483-501, Yokohama.
	63	Mitchinson, C., et al., "Protein Engineering of Disulfide Bonds in Subtilisin BPN", BIOCHEMISTRY, Vol. 28, No. 11, pp. 4807-4815 (1989).
	64	Monfardini, C. et al., "A Branched Monoethoxy Poly(ethylene glycol) for Protein Modification", BICONJUGATE CHEMISTRY, Vol. 6, No. 1, pp. 62-69 (1995).
	65	Nishimura, H. et al., "Improved Modification of Yeast Uricase with Polyethylene Glycol, Accompanied with Non-immunoreactivity Towards Anti-Uricase Serum and High Enzymic Activity", ENZYME, Vol. 26, pp. 49-53 (1981).
	66	Nucci, M. L., et al., "Immunogenicity of Polyethylene Glycol-Modified Superoxide Dismutase and Catalase", J. FREE RADICALS IN BIOLOGY & MEDICINE, Vol. 2, pp. 321-325 (1986).
67	Nucci, M.L. et al., "The Therapeutic Value of Poly(ethylene glycol)-modified Proteins", ADVANCED DRUG DELIVERY REVIEWS, Vol. 6, pp. 133-149 (1991).	
<i>WWR</i> ↓	68	Ohta, M. et al., "Preparation of a Dextran-Protease Conjugate and its Application to Cosmetic Use", KANEBO, LTD., Cosmetics & Toiletries® Magazine, Vol. 111, (1996).
EXAMINER <i>W. L. Moore</i>		DATE CONSIDERED <i>15 Oct 2000</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Patent and Trademark Office - U.S. DEPARTMENT OF COMMERCE



FORM PTO-1449
Sheet 3 of 3


LIST OF DOCUMENTS CITED BY APPLICANTS (Use several sheets if necessary)	ATTY. DOCKET NO. 7070	SERIAL NO. 09/09/646,984
	APPLICANT Rubingh et al.	
	FILING DATE 9/25/2000	GROUP <u>1633 1652</u>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>am</i> ↑ ↓ <i>am</i>	69	Reay, P.A. et al., "Use of Global Amino Acid Replacements to Define the Requirements for MHC Binding and T Cell Recognition of Moth Cytochrome c (93-103)", JOURNAL OF Immunology, Vol. 152, NO. 8, pp. 3946-3957 (1994).
	70	Ritz, H.L. et al., "Respiratory and Immunological Responses of Guinea Pigs to Enzyme-Containing Detergents: A Comparison of Intratracheal and Inhalation Modes of Exposure", FUNDAMENTAL AND APPLIED TOXICOLOGY, Vol. 21, pp. 31-37 (1993).
	71	Robinson, M.K. et al., "Specific Antibody Responses to Subtilisin Carlsberg (Alcalase) in Mice: Development of an Intranasal Exposure Model", FUNDAMENTAL AND APPLIED TOXICOLOGY, Vol. 34, pp. 15-24 (1996).
	72	Savoca, K.V. et al., "Preparation of a Non-immunogenic Agrinase by the Covalent Attachment of Polyethylene Glycol", BIOCHEMICA ET BIOPHYSICA ACTA, Vol. 578, pp. 47-53 (1979).
	73	Siezen, R.J. et al., "Homology Modelling and Protein Engineering Strategy of Subtilases, the Family of Subtilisin-Like Serine Proteases", PROTEIN ENGINEERING, Vol. 4, No. 7, pp. 719 - 737 (1991).
	74	Walsh, B.J. and M.E.H. Howden, "A Method for the Detection of IgE Binding Sequences of Allergens Based on a Modification of Epitope Mapping", JOURNAL OF IMMUNOLOGICAL METHODS, Vol. 121, pp. 275 - 280 (1989).
	75	Wells, J. A., et al., "Recruitment of Substrate-Specificity Properties From One Enzyme into a Related One by Protein Engineering", PROC. NATL. ACAD. SCI. USA, Vol. 84, pp. 5167-5171 (Aug 1987).
EXAMINER <i>William W. Mow</i>		DATE CONSIDERED <i>15 October 2002</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Patent and Trademark Office - U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box → [+]



PTO/SB08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 1

COMPLETE IF KNOWN

Application Number	09/646,984
Confirmation Number	Unknown
Filing Date	9/25/2000
First Named Inventor	D. N. Rubingh
Group Art Unit	1633 1682
Examiner Name	Not Assigned
Attorney Docket Number	7070

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	U.S. PATENT DOCUMENT Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
Worm	01	5,543,302		Boguslawski et al.	08/06/96	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
Worm	02	DE	2 206 826		Schering AG	08/16/73		
Worm	03	EP	0 471 125	A1	Kanebo, Ltd.	12/19/92		
Worm	04	EP	0 405 901	A	Unilever PLC	01/02/91	duplicate	
Worm	05	WO	87/04461	A1	Amgen Inc.	07/30/87		
	06	WO	88/08033	A1	Amgen Inc.	10/20/88		
	07	WO	88/08165	A1	Genex Corp.	10/20/88		
	08	WO	96/09396	A1	Univ of Maryland	03/28/96		
	09	WO	98/23732	A2	Genencor Int'l, Inc.	06/04/98		
	10	WO	99/37324	A1	Genencor Int'l, Inc.	07/29/99		
	11	WO	99/48918	A1	Procter & Gamble	09/30/99		
	12	WO	99/49056	A1	Procter & Gamble	09/30/99		
	13	WO	00/28007	A2	Genencor Int'l, Inc.	05/18/00		
Worm	14	WO	00/37658	A2	Genencor Int'l, Inc.	06/29/00		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
Worm	15	Gundlach, B.R., et al., "Determination of T Cell Epitopes with Random Peptide Libraries", Journal of Immunological Methods , Vol. 192, pp. 149-155 (1996).	
Worm	16	Siezen, R.J., et al., "Subtilases: The Superfamily of Subtilisin-like Serine Proteases", Protein Science , Vol. 6, No. 3, pp 501-523 (1997).	
Worm	17	Yang, M-L., et al., "Chemical Modification of Cobrotoxin with Bifunctional Reagent, 1,5-Difluoro-2,4-Dinitrobenzene", Kaohsiung J. Med. Sci. , Vol. 4, pp 503-513 (1988).	
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.


Please type a plus sign (+) inside this box → [+]

PTO/SB08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p style="text-align: center;">Substitute for form 1449A/PTO</p> <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p> <div style="text-align: center;">  </div> <p>SHEET 1 of 2</p>	<p style="text-align: center;">COMPLETE IF KNOWN</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">Application Number</td> <td>09/646,984</td> </tr> <tr> <td>Confirmation Number</td> <td>3685</td> </tr> <tr> <td>Filing Date</td> <td>9/25/2000</td> </tr> <tr> <td>First Named Inventor</td> <td>D. N. Rubingh</td> </tr> <tr> <td>Group Art Unit</td> <td>1652</td> </tr> <tr> <td>Examiner Name</td> <td>W. W. Moore</td> </tr> <tr> <td>Attorney Docket Number</td> <td>7070</td> </tr> </table>	Application Number	09/646,984	Confirmation Number	3685	Filing Date	9/25/2000	First Named Inventor	D. N. Rubingh	Group Art Unit	1652	Examiner Name	W. W. Moore	Attorney Docket Number	7070
Application Number	09/646,984														
Confirmation Number	3685														
Filing Date	9/25/2000														
First Named Inventor	D. N. Rubingh														
Group Art Unit	1652														
Examiner Name	W. W. Moore														
Attorney Docket Number	7070														

RECEIVED
 JUN 18 2002
 TECH CENTER 1600/2690

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	U.S. PATENT DOCUMENT Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
uwn	01	5,766,898	A	Loeburg	06/16/1998	
uwn	02	5,972,339	A	Walker	10/26/1999	
uwn	03	5,985,264	A	Metzger et al.	11/16/1999	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT Office ³ Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
uwn	04	EP 0 130 756	A1	Genetech, Inc.	01/09/1985		
uwn	05	EP 0 260 105	B1	Genencor, Inc.	03/16/1988		
	06	EP 0 398 539	B1	Amgen Inc.	11/22/1990	duplicate	
	07	WO 87/05060	A1	Genex Corp.	08/27/1987	duplicate	
uwn	08	WO 88/07578	A1	Genentech, Inc.	10/06/1988		
	09	WO 88/08028	A1	Genex Corp.	10/20/1988	duplicate	
uwn	10	WO 88/08164	A1	Genex Corp.	10/20/1988		
uwn	11	WO 93/25667	A1	Scripps Research	12/23/1993		
	12	WO 95/07991	A2	Procter & Gamble	03/23/1995	duplicate	
uwn	13	WO 95/20039	A2	Carlsberg A/S	07/27/1995		
	14	WO 99/33868	A2	Smith Kline Beech.	07/08/1999		
	15	WO 99/40936	A2	Amer. Cyanamid	08/19/1999		
	16	WO 99/41369	A2	Maxygen, Inc.	08/19/1999		
	17	WO 99/42097	A1	Dovetail Tech., Inc.	08/26/1999		
	18	WO 99/44635	A1	Med. College of OH	09/10/1999		
	19	WO 99/45904	A1	Allergenic Inc.	09/16/1999		
uwn	20	WO 00/09707	A1	Genencor Int'l., Inc.	02/24/2000		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
uwn	21	Atassi, M.Z., et al., "Structure, Activity, and Immune (T and B Cell) Recognition of Botulinum Neurotoxins", Critical Reviews in Immunology , Vol. 19, pp. 219-260 (1999)	
	22	Blaser, K., "Allergen Dose Dependent Cytokine Production Regulates Specific IgE and IgG Antibody Production", New Horizons in Allergy Immunotherapy , Sehon et al. (Ed.) Plenum Press, N.Y. (1996)	
	23	Cui, J., et al., "Inhibition of T Helper Cell Type 2 Cell Differentiation and Immunoglobulin E Response by Ligand-activated Vα14 Natural Killer T Cells", J. Exp. Med. , Vol. 190, No. 6, pp. 783-792, (9/20/1999)	
	24	Deml, L., et al., "Immunostimulatory CpG Motifs Trigger a T Helper-1 Immune Response to Human Immunodeficiency Virus Type-1 (HIV-1) gp 160 Envelope Proteins", Clin Chem Lab Med , Vol. 37, No. 3, pp. 199-204 (1999)	
	25	Ferru, I., et al., "Comparison of the Immune Response Elicited by a Free Peptide and a Lipopeptide Construct", P ptide Research , Vol. 9, No. 3, pp. 136-143 (1996)	
uwn	26	Haack, T., et al., "D-Amino Acids in Protein De Novo Design. II. Protein-diastereomerism Versus Protein-enantiomerism", Letters in Peptide Science , Vol. 4, pp. 377-386 (1997)	

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 2 of 2

COMPLETE IF KNOWN

Application Number	09/646,984
Confirmation Number	3685
Filing Date	9/25/2000
First Named Inventor	D. N. Rubingh
Group Art Unit	1652
Examiner Name	W. W. Moore
Attorney Docket Number	7070

RECEIVED
JUN 18 2002
TECH CENTER 160012900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS (continued)

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
Wern	27	Herve, M., et al., "On the Immunogenic Properties of Retro-Inverso Peptides. Total Retro-Inversion of T-Cell Epitopes Causes a Loss of Binding to MHC II Molecules", Molecular Immunology , Vol. 34, No. 2, pp. 157-163 (1997)	
↑	28	Hoyne, G. F., et al., "Peptide-Mediated Regulation of the Allergic Immune Response", Immunology and Cell Biology , Vol. 74, pp. 180-186 (1996)	
	29	Ikagawa, S., MD., et al., "Single Amino Acid Substitutions on a Japanese Cedar Pollen Allergen (Cry j 1)-derived Peptide Induced Alterations in Human T Cell Responses and T Cell Receptor Antagonism", J. Allergy Clin. Immuno. , Vol. 97, No. 1, Part 1, pp. 53-64 (Jan 1996)	
	30	Lofthouse, S. A., et al., "Induction of T ₂ (cytotoxic lymphocyte) and/or T ₁ (antibody) Responses to a Mucin-1 tumour Antigen", Vaccine , Vol. 15, No. 14, pp. 1586-1593 (1997)	
	31	Maillere, B., et al., "Probing Immunogenicity of a T-Cell Epitope by L-Alanine and D-Amino Acid Scanning", Molecular Immunology , Vol. 32, No. 14/15, pp. 1073-1080 (1995)	
	32	McKee, H. J., et al., "T Cell Cytokine Responses to Cartilage Aggrecan in BALB/c Mice", Biochemical Society Transactions , Vol. 25, p 311S (1997)	
	33	Moore, A., et al., "The Adjuvant Combination Monophosphoryl Lipid A and QS21 Switches T Cell Responses Induced With a Soluble Recombinant HIV Protein from Th2 and Th1", Vaccine , Vol. 17, pp. 2517-2527 (1999)	
	34	Rosenthal, K. S., et al., "Immunization with a LEAPS™ Heteroconjugate Containing a CTL Epitope and a Peptide from Beta-2-microglobulin Elicits a Protective and DTH Response to Herpes Simplex Virus Type 1", Vaccine , Vol. 17, pp. 535-542 (1999)	
	35	Sinha, P., et al., "A Minimized Fc Binding Peptide from Protein A Induces Immunocyte Proliferation and Evokes Th1-Type Response in Mice", Biochemical and Biophysical Research Communications , Vol. 258, pp. 141-147 (1999)	
	36	Specht, C., et al., "The Murine (H-2 ^k) T-Cell Epitopes of Bee Venom Phospholipase A ₂ Lie Outside the Active Site of the Enzyme", Int Arch Allergy Immunol , Vol. 112, pp. 226-230 (1997)	
↓	37	Wiedermann, U., et al., "Effects of Adjuvants on the Immune Response to Allergens in a Murine Model of Allergen Inhalation: Cholera Toxin Induces a Th1-like Response to Bet V 1, the Major Birch Pollen Allergen", Clin Exp Immunol , Vol. 111, pp. 144-151 (1998)	
Wern	38	Zimmerman, D. H., et al., "Immunization with Peptide Heteroconjugates Primes a T Helper Cell Type 1-Associated Antibody (IgG2a) Response that Recognizes the Native Epitope on the 38-kDa Protein of <i>Mycobacterium tuberculosis</i> ", Vaccine Research , Vol. 5, No. 2, pp. 103-118 (1996)	
EXAMINER	DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.